BSE:500680

Stock Analysis Report

Executive Summary

Pfizer Limited manufactures, markets, trades in, and exports pharmaceutical products in India and internationally.

Snowflake

Fundamentals

Excellent balance sheet with acceptable track record.


Similar Companies

Share Price & News

How has Pfizer's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.6%

500680

3.9%

IN Pharmaceuticals

3.8%

IN Market


1 Year Return

16.9%

500680

-17.5%

IN Pharmaceuticals

6.0%

IN Market

Return vs Industry: 500680 exceeded the Indian Pharmaceuticals industry which returned -17.5% over the past year.

Return vs Market: 500680 exceeded the Indian Market which returned 6% over the past year.


Shareholder returns

500680IndustryMarket
7 Day1.6%3.9%3.8%
30 Day-2.1%-4.4%2.9%
90 Day0.03%-2.0%2.9%
1 Year17.8%16.9%-16.8%-17.5%8.2%6.0%
3 Year79.9%75.6%-25.4%-27.0%23.0%16.7%
5 Year107.7%99.8%-10.5%-13.2%43.6%30.0%

Price Volatility Vs. Market

How volatile is Pfizer's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Pfizer undervalued compared to its fair value and its price relative to the market?

32.72x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 500680 (₹3218.75) is trading above our estimate of fair value (₹357.19)

Significantly Below Fair Value: 500680 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 500680 is poor value based on its PE Ratio (32.7x) compared to the Pharmaceuticals industry average (15.7x).

PE vs Market: 500680 is poor value based on its PE Ratio (32.7x) compared to the Indian market (13.1x).


Price to Earnings Growth Ratio

PEG Ratio: 500680 is poor value based on its PEG Ratio (2.9x)


Price to Book Ratio

PB vs Industry: 500680 is overvalued based on its PB Ratio (4.9x) compared to the IN Pharmaceuticals industry average (1.5x).


Next Steps

Future Growth

How is Pfizer forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

11.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 500680's forecast earnings growth (11.3% per year) is above the savings rate (7.6%).

Earnings vs Market: 500680's earnings (11.3% per year) are forecast to grow slower than the Indian market (18% per year).

High Growth Earnings: 500680's earnings are forecast to grow, but not significantly.

Revenue vs Market: 500680's revenue (11.3% per year) is forecast to grow slower than the Indian market (11.3% per year).

High Growth Revenue: 500680's revenue (11.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 500680's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Pfizer performed over the past 5 years?

25.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: 500680's earnings have grown significantly by 25.4% per year over the past 5 years.

Accelerating Growth: 500680's earnings growth over the past year (14%) is below its 5-year average (25.4% per year).

Earnings vs Industry: 500680 earnings growth over the past year (14%) underperformed the Pharmaceuticals industry 14.4%.


Return on Equity

High ROE: 500680's Return on Equity (14.9%) is considered low.


Return on Assets

ROA vs Industry: 500680 has a higher Return on Assets than the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: 500680 has significantly improved its Return on Capital Employed over the past 3 years.


Next Steps

Financial Health

How is Pfizer's financial position?


Financial Position Analysis

Short Term Liabilities: 500680's short term assets (₹27.2B) exceeds its short term liabilities (₹8.9B)

Long Term Liabilities: 500680's short term assets (27.2B) exceeds its long term liabilities (369.6M)


Debt to Equity History and Analysis

Debt Level: 500680's debt to equity ratio (0.08%) is considered satisfactory

Reducing Debt: Insufficient data to determine if 500680's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: 500680's debt is well covered by operating cash flow (3912.4%).

Interest Coverage: 500680 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: 500680 has a low level of unsold assets or inventory.

Debt Coverage by Assets: 500680's debt is covered by short term assets (assets are 1086.668000x debt).


Next Steps

Dividend

What is Pfizer's current dividend yield, its reliability and sustainability?

0.70%

Current Dividend Yield


Dividend Yield vs Market

company0.7%marketbottom25%0.6%markettop25%2.4%industryaverage0.9%forecastin3Years0.8%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: 500680's dividend (0.7%) is higher than the bottom 25% of dividend payers in the Indian market (0.6%).

High Dividend: 500680's dividend (0.7%) is low compared to the top 25% of dividend payers in the Indian market (2.42%).

Stable Dividend: 500680's dividend payments have been volatile in the past 10 years.

Growing Dividend: 500680's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (22.9%), 500680's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

What is the CEO of Pfizer's salary, the management and board of directors tenure and is there insider trading?

6.7yrs

Average management tenure


CEO

S. Sridhar (51yo)

3.6yrs

Tenure

₹35,526,571

Compensation

Mr. S. Sridhar has been the Chief Executive Officer, Managing Director & Lead – Essential Health Portfolio of Pfizer Limited since March 18, 2016. Mr. Sridhar served as Business Unit Head of Pfizer Limited ...


CEO Compensation Analysis

Compensation vs. Market: S.'s total compensation ($USD499.84K) is about average for companies of similar size in the Indian market ($USD621.42K).

Compensation vs Earnings: S.'s compensation has been consistent with company performance over the past year.


Management Age and Tenure

6.7yrs

Average Tenure

52yo

Average Age

Experienced Management: 500680's management team is seasoned and experienced (6.7 years average tenure).


Board Age and Tenure

6.4yrs

Average Tenure

57yo

Average Age

Experienced Board: 500680's board of directors are considered experienced (6.4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Prajeet Nair

    Compliance Officer & Company Secretary

    • Tenure: 12.1yrs
    • Compensation: ₹5.35m
  • S. Sridhar (51yo)

    CEO, MD

    • Tenure: 3.6yrs
    • Compensation: ₹35.53m
  • Samir Kazi

    Senior Director of Legal

    • Tenure: 9.8yrs
  • Vivek Dhariwal (52yo)

    Executive Director of Technical Operations & Whole-Time Director

    • Tenure: 7.4yrs
    • Compensation: ₹25.25m
  • Sharad Goswami

    Senior Director of Public Affairs

    • Tenure: 0yrs
  • Milind Patil (55yo)

    CFO, Executive Director of Finance & Executive Director

    • Tenure: 0.9yrs
    • Compensation: ₹9.94m
  • Shilpi Singh

    Director of Human Resources

    • Tenure: 0yrs

Board Members

  • Meena Ganesh (55yo)

    Additional Independent Director

    • Tenure: 0.6yrs
    • Compensation: ₹150.00k
  • Rajendra Shah (88yo)

    Non Executive Independent Chairman

    • Tenure: 0yrs
    • Compensation: ₹2.20m
  • Sunil Lalbhai (59yo)

    Non Executive Independent Director

    • Tenure: 4.7yrs
    • Compensation: ₹1.86m
  • Pradip Shah (66yo)

    Non-Executive Independent Director

    • Tenure: 19.8yrs
    • Compensation: ₹2.29m
  • Uday Khanna (70yo)

    Non Executive Independent Director

    • Tenure: 7.4yrs
    • Compensation: ₹2.23m
  • S. Sridhar (51yo)

    CEO, MD

    • Tenure: 3.6yrs
    • Compensation: ₹35.53m
  • Vivek Dhariwal (52yo)

    Executive Director of Technical Operations & Whole-Time Director

    • Tenure: 7.4yrs
    • Compensation: ₹25.25m
  • Milind Patil (55yo)

    CFO, Executive Director of Finance & Executive Director

    • Tenure: 0.9yrs
    • Compensation: ₹9.94m

Company Information

Pfizer Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pfizer Limited
  • Ticker: 500680
  • Exchange: BSE
  • Founded: 1950
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹147.251b
  • Shares outstanding: 45.75m
  • Website: https://www.pfizerindia.com

Number of Employees


Location

  • Pfizer Limited
  • The Capital
  • 1802 / 1901, 18th Floor
  • Mumbai
  • Maharashtra
  • 400051
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
500680BSE (Mumbai Stock Exchange)YesEquity SharesININRMar 1999
PFIZERNSEI (National Stock Exchange of India)YesEquity SharesININRMar 1999

Biography

Pfizer Limited manufactures, markets, trades in, and exports pharmaceutical products in India and internationally. It offers its various products in various therapeutic areas, including anti-allergic, anti ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 12:34
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.